<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119475">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081170</url>
  </required_header>
  <id_info>
    <org_study_id>2013-12-066</org_study_id>
    <nct_id>NCT02081170</nct_id>
  </id_info>
  <brief_title>The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of intravitreal autologous
      platelet concentrate (APC) injection during the surgery for refractory macular holes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>macular hole closure</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>best-corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metamorphopsia score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety outcome</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>frequency and severity of ocular adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Macular Hole With High Myopia (Spherical Equivalent ≤ -6.0 Diopters) or,</condition>
  <condition>Large Size Macular Hole (Diameter &gt; 600 Microns) or</condition>
  <condition>Recurred or Failed Macular Hole From Previous Surgery</condition>
  <condition>or Chronic Macular Hole (Symptom Duration &gt; 6 Months)</condition>
  <arm_group>
    <arm_group_label>autologous platelet concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous platelet concentrate</intervention_name>
    <description>pars plana vitrectomy
internal limiting membrane removal
Fluid-air exchange
Intravitreal autologous platelet concentrate injection
Intravitreal gas (14% C3F8) injection
Keep prone position for 7-14 days after surgery</description>
    <arm_group_label>autologous platelet concentrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macular hole with any of following condition

               -  High myopia (spherical equivalent ≤ -6.0 Diopters)

               -  Large size macular hole (Diameter &gt; 600 microns)

               -  Recurred or failed macular hole from previous surgery

               -  Chronic macular hole (symptom duration &gt; 6 months)

        Exclusion Criteria:

          -  Systemic infection

          -  Hematologic disease

          -  Severe maculopathy including severe diabetic retinopathy, advanced age-related
             macular degeneration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ga Eun Cho, MD</last_name>
    <phone>+82-3410-3548</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>0000</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Woong Kang, MD</last_name>
      <phone>+82-2-3410-3562</phone>
    </contact>
    <contact_backup>
      <last_name>Ga Eun Cho, MD</last_name>
      <phone>+82-2-3410-3548</phone>
    </contact_backup>
    <investigator>
      <last_name>Se Woong Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ga Eun Cho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Perforations</mesh_term>
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
